早产分娩
钙通道阻滞剂和催产素拮抗药阿托西班是最值得推荐的宫缩抑制剂，但备选药品诸如beta-mimetic，消炎痛和硫酸镁在一些国家的指引里面是仍然推荐的。
Available guidelines
| Region | Country | Date | Source url | Recommendations for tocolytic treatment |
| Europe | Austria | 2005 | OEGGG | 1. Atosiban 2. Beta-mimetics or calcium channel blockers |
| Europe | Belgium | 2014 |
| GGOLFB: KCE: Fetal fibronectin, phosphorylated insulin-like growth factor binding protein-1 and cervical length measurement tests recommended VVOG: |
| Europe | Czech Republic | 2012 | ČGPS ČLS JEP | No first-line recommendation • Beta-mimetics or atosiban |
| Europe | Denmark | 2013 | DSOG | 1. Atosiban 2. Calcium channel blockers, beta-mimetics or non-steroidal anti-inflammatory dru
|
| Europe | Finland | 2011 | Link | No first-line recommendation • Calcium channel blockers or atosiban |
| Europe | France | 2014 | CNGOF | No first-line recommendation |
| Europe | Germany | n/a | DGGG | No first-line recommendation • Atosiban, fenoterol or nifedipine |
| Europe | Greece | 2014 | HSOG | No first-line recommendation • Nifedipine or atosiban |
| Europe | Italy | 2013 | n/a | No first-line recommendation, treatments recommended according gestational week Beta-mimetics are strongly not recommended |
| Europe | The Netherlands | 2012 | NVOG | No first-line recommendation Atosiban has a slight preference in complicated pregnancies |
| Europe | Norway | 2014 | NGF | 1. Atosiban 2. Nifedipine 3. Indomethacin |
| Europe | Portugal | n/a | n/a | 1. Atosiban 2. Nifedipine 3. Indomethacin |
| Europe | Romania | 2010 | Link | 1. Atosiban 2. Nifedipine 3. Hexoprenaline, terbutaline or ritodrine 4. Indomethacin 5. Magnesium sulphate 6. Nitroglycerin 7. Betamethasone or dexamethasone |
| Europe | Russia | 2013 | Link | 1. Nifedipine in 50% cases of PTL 2. Atosiban in 20% cases of PTL 3. Hexoprenaline in 20% of PTL |
| Europe | Spain | 2014 | SEGO | No first-line recommendation • Atosiban has fewer failures within 48 hours • Nifedipine may be associated with a longer postponement of delivery • Nifedipine has a higher risk of adverse events compared with atosiban • Atosiban is the choice of treatment for twin deliveries |
| Europe | Sweden | n/a | n/a | • Atosiban is used as first-line treatment at university hospitals and most regional hospitals |
| Europe | United Kingdom | 2011 | RCOG | • Atosiban or nifedipine Atosiban is 500 times more expensive than nifedipine |
| South America | Argentina | n/a | n/a | Draft guidelines Nifedipine is not considered |
| South America | Brazil | 2013 | FEBRASGO | • Beta-mimetics are preferred but have a high risk of side effects that compromise efficacy • Atosiban has high efficacy and low risk of adverse events, but is expensive • Nifedipine requires more evidence to be considered as a recommendation, and there is a need for standardised dosage |
| South America | Mexico | 2008 | CENETEC | Atosiban is recommended to be used as follows: • Initial dose of 6.7 mg • Followed by an infusion of 300 mcg/min for 3 hours • Followed by 100 mcg/min until 48 hours of treatment |
| Asia | China | 2014 | RANZCOG | Follow RANZCOG guidelines 1. Magnesium sulphate 2. Beta-mimetics 3. Nifedipine 4. Indomethacin 5. Atosiban |
| Asia | Hong Kong | 2011 | RCOG | Follow RCOG guidelines |
| Asia | Japan | 2011 | JSOG | 1. Ritodrine hydrochloride 2. Magnesium sulphate |
| Asia | Malaysia | n/a | n/a | 1. Terbutaline 2. Ritodrine |
| Asia | Singapore | 2011 | RCOG | Follow RCOG guidelines 1. Beta-mimetics 2. Other pharmacological agents, including: nitric oxide donors, magnesium sulphate, indomethacin, nifedipine and atosiban |
| Asia | South Korea | 2014 | KSOG | 1. Ritodrine 2. Atosiban |
| Asia | Thailand | n/a | n/a | 1. Beta-mimetics (terbutaline) 2. Calcium channel blockers (nifedipine) 3. Magnesium sulphate |
| Asia | The Philippines | 2014 | n/a | 1. Beta-mimetics 2. Nifedipine 3. Progesterone 4. Atosiban |
| Asia | Vietnam | 2012 | n/a | 1. Nifedipine 2. Salbutamol 3. Atosiban |
| Australasia | New Zealand | 2011 | RANZCOG | • Nifedipine |
| Middle east | Lebanon | 2014 | • CNGOF: Atosiban, beta-mimetics or calcium channel blockers Choice of therapy depends on which guidelines (France or UK) each hospital follows | |
| Middle east | Israel | 2014 | Link | No first-line recommendation • Treatment options include: calcium channel blockers, prostaglandins inhibitors, atosiban and beta-mimetics |
| Middle east | Saudi Arabia | 2011 | Link | • Nifedipine and atosiban have comparable effectiveness in delaying birth for up to seven days Tocolysis should not be used where there is a contraindication to prolonging pregnancy |
| Africa | South Africa | n/a | n/a | No first-line recommendation • Atosiban • Nifedipine |